ICC joint venture shareholder communication agreement with the aim of a Europe-wide distribution. The issuer is responsible for the content. Shareholder communication from the President of the Nevada-based and listed on the Frankfurt Stock Exchange ICC International Coaltition capital, Inc., announces that the company as of 03 June 2008 contract has completed an irrevocable joint venture with the company C.Y.L Pharmaceuticals GmbH. The contract States that the patents and rights of the company C.Y.L Pharmaceuticals GmbH on the cancer drug KABRAWALA, is currently owned joint-stock company be brought into a foundation. If you would like to know more then you should visit Risa Miller. The ICC then holds a stake of 49% in this joint-stock company.
The medicine Kabir has positively completed phase 2 of the approval and it is currently preparing a phase 3 study. The funding of the phase 3, is taken over by the currently still in establishment of new joint-stock company. The still-unapproved medicines Kabir in addition to the application in studies is currently also employed as a final healing attempt from treated patients at the request of patients. According to current valuations, which has given the ICC contract, estimated annual sales of the drug Kabir, after marketing authorization in Germany, currently to about 550 million euros and in Europe, excluding the Eastern European countries, to approximately 2.6 billion euros. Possible related realignment of the company by the newly occupied management and the multinational investor consortium of ICC related was that participation and the.